NRSN
Neurosense Therapeutics Ltd
NASDAQ: NRSN · HEALTHCARE · BIOTECHNOLOGY
$0.80
-0.72% today
Updated 2026-04-29
Market cap
$26.53M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.44
Dividend yield
—
52W range
$1 – $3
Volume
0.2M
Neurosense Therapeutics Ltd (NRSN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | $3000.00 | $3000.00 | $89000.00 | $97000.00 | $22000.00 | — |
| Gross profit | — | $-3000.00 | $-3000.00 | $-89000.00 | $-97000.00 | $-22000.00 | — |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $898000.00 | $2.50M | $3.08M | $6.42M | $7.27M | $5.70M | $6.23M |
| SG&A | $337000.00 | $393000.00 | $2.50M | $7.14M | $4.78M | $4.20M | $4.86M |
| Operating income | $-1.24M | $-2.89M | $-5.59M | $-13.55M | $-12.05M | $-9.90M | $-11.09M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-1.25M | $-2.83M | $-2.88M | $-12.23M | $-9.64M | $-9.88M | $-11.07M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-2.49M | $-2.83M | $-2.89M | $-12.32M | $-9.66M | $-9.90M | $-11.09M |
| Interest expense | $5000.00 | $1000.00 | $1.15M | $15000.00 | $550000.00 | $311000.00 | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1.23M | $-2.83M | $-4.04M | $-12.34M | $-10.11M | $-10.21M | $-11.13M |
| Net income growth (YoY) | — | -130.5% | -42.9% | -205.4% | +18.1% | -1.0% | -9.0% |
| Profit margin | — | — | — | — | — | — | — |